78 NHS trusts to receive new cancer screening machines

78 trusts will receive funding for new machines that will improve patient experience and lead to earlier diagnosis | via Department of Health and Social Care

The Rotherham NHS Foundation Trust is one of 78 trusts that will benefit from funding for new cancer testing and detection technology.  The new machines will improve screening and early diagnosis of cancer, and are part of the government’s commitment to ensure 55,000 more people survive cancer each year.

mri-2813911_1920

Last month the Prime Minister announced the extra £200 million in funding for new cancer screening equipment. 78 trusts will receive funding over the next 2 years to replace, refurbish and upgrade:

  • CT and MRI scanners – bringing in alternatives with lower radiation levels
  • breast screening imaging and assessment equipment

Replacing and upgrading machines will improve efficiency by:

  • making them easier to use
  • being quicker to scan and construct images
  • reducing the need to re-scan

This new equipment also brings new capability, with many machines enabled for artificial intelligence (AI) so the NHS is ready for the challenges of the future.

Each trust has been allocated funding for new machines based on an assessment of local infrastructure and local population need. They will all contribute to the NHS Long Term Plan’s goal of catching three-quarters of all cancers earlier when they are easier to treat.

Full story at Department of Health and Social Care

See also: Full list of trusts that will receive funding.

International alliance sets bold research ambition to detect the (almost) undetectable

Cancer Research UK| October  2019 | International alliance sets bold research ambition to detect the (almost) undetectable

Developing radical new strategies and technologies to detect cancer at its earliest stage is the bold ambition of a new transatlantic research alliance, announced today by Cancer Research UK and partners.

Cancer Research UK is setting out a bold ambition to jump-start this under-explored field of research, collaborating with teams of scientists from across the UK and the US.

The International Alliance for Cancer Early Detection (ACED) is a partnership between Cancer Research UK, Canary Center at Stanford University, the University of Cambridge, the OHSU Knight Cancer InstituteUCL and the University of Manchester.

Scientists in the Alliance will work together at the forefront of technological innovation to translate research into realistic ways to improve cancer diagnosis, which can be implemented into health systems. Potential areas of research include: ​

  • Developing new improved imaging techniques and robotics, to detect early tumours and pre-cancerous lesions
  • Increasing understanding of how the environment surrounding a tumour influences cancer development
  • Developing less invasive and simpler detection techniques such as blood, breath and urine tests, which can monitor patients who are at a higher risk of certain cancers
  • Searching for early stress signals sent out from tumours or surrounding damaged tissue as a new indication of cancer
  • Looking for early signs of cancer in surrounding tissue and fluids to help diagnose hard to reach tumours
  • Harnessing the potential of artificial intelligence and big data to look for signs of cancer that are undetectable to humans.

As part of the Cancer Research UK’s early detection strategy, the charity will invest an essential cash injection of up to £40 million over the next five years into ACED. Stanford University and the OHSU Knight Cancer Institute will also significantly invest in the Alliance, taking the total potential contributions to more than £55 million (Source: Cancer Research UK).

Full details of the project are available from Cancer Research UK

See also:

BMJ New UK and US research alliance aims to detect cancer earlier and improve screening

Targeted breast cancer treatment approved for NHS use in England

Cancer Research UK | October 2019 | Targeted breast cancer treatment approved for NHS use in England

A new treatment for early stage breast cancer will be made available for certain patients on the NHS in England.

Following the recommendation from the National Institute for Health and Care Excellence (NICE), neratinib (Nerlynx) will be offered as an extended treatment for breast cancer patients who’ve had another targeted treatment, trastuzumab (Herceptin), within the last year.

cancer-icon-2797418_640.png

The new treatment is said to “significantly reduce the proportion of breast cancer relapses”, according to short-term trial data.

Neratinib blocks the cancer growth by interfering with chemical signals sent between cells.

It’s recommended for use for patients whose cancer tests positive for hormone receptors and a molecule called HER2. The treatment will only be available to adults who’ve been treated with trastuzumab within the last year, and where trastuzumab was used after initial treatment to help stop their cancer coming back.

This is the first treatment available for patients who have previously taken trastuzumab that maintain the intended effect of that treatment (adjuvant therapy).

Further criteria which patients will have to meet in order to access the drug include:

  • Trastuzumab is the only treatment they’ve taken that targets the molecule HER2
  • If trastuzumab was given before surgery, there were still signs of cancer in the tissue samples removed during surgery (Source: Cancer Research UK)

Read the press release from Cancer Research UK

Full details available from NICE 

Adult screening programmes review

Report of The Independent Review of Adult Screening Programmes in England | NHS England 

This report makes recommendations for overhauling national screening programmes to improve earlier diagnosis and cancer survival.  It calls for people to be given much greater choice over when and where they are screened; increase uptake through social media campaigns and text reminders; and roll out local initiatives which have boosted uptake.

Full detail at NHS England

See also: NHS England news release

Music in palliative care

Pommeret, S. et al. | Music in palliative care: a qualitative study with patients suffering from cancer | BMC Palliative Care | Volume 18, Article number 78 (2019)

radio-777219_1920

Abstract

Background

The palliative care unit is an emotionally challenging place where patients and their families may feel at loss. Art can allow the expression of complex feelings. We aimed to examine how cancer patients hospitalized in the palliative care unit experienced a musical intervention.

Methods

We conducted a qualitative study based on semi-structured interviews. The study took place in a palliative care unit from 18 January 2017 to 17 May 2017. Two artists performed in the palliative care unit once a week from 9:30 am to 5:30 pm. The data from patient interviews were analysed based on an inductive approach to the verbatim accounts.

Results

The accounts we gathered led us to weigh the positive emotions engendered by this musical intervention against the potential difficulties encountered. The artists opened a parenthesis in the care process and brought joy and well-being to the palliative care unit. Patients also encountered difficulties during the intervention: reference to an altered general state, to loss of autonomy; a sense of the effort required, of fatigue; an adaptation period; reference to the end of life, to death; a difficulty in choosing songs.

Conclusions

Although music appeared to benefit the patients, it sometimes reminded them of their altered state. The difficulties experienced by patients during the experience were also related to physical exhaustion. Additional studies are needed to determine the benefits of music for patients and their families in the palliative care unit.

Full document at BMC Palliative Care

Depression and anxiety among people living with and beyond cancer

Niedzwiedz, C. L. et al. | Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority | BMC Cancer | Volume 19, Article number: 943 (2019)

Abstract

Background

A cancer diagnosis can have a substantial impact on mental health and wellbeing. Depression and anxiety may hinder cancer treatment and recovery, as well as quality of life and survival. We argue that more research is needed to prevent and treat co-morbid depression and anxiety among people with cancer and that it requires greater clinical priority. For background and to support our argument, we synthesise existing systematic reviews relating to cancer and common mental disorders, focusing on depression and anxiety.

We searched several electronic databases for relevant reviews on cancer, depression and anxiety from 2012 to 2019. Several areas are covered: factors that may contribute to the development of common mental disorders among people with cancer; the prevalence of depression and anxiety; and potential care and treatment options. We also make several recommendations for future research. Numerous individual, psychological, social and contextual factors potentially contribute to the development of depression and anxiety among people with cancer, as well as characteristics related to the cancer and treatment received. Compared to the general population, the prevalence of depression and anxiety is often found to be higher among people with cancer, but estimates vary due to several factors, such as the treatment setting, type of cancer and time since diagnosis. Overall, there are a lack of high-quality studies into the mental health of people with cancer following treatment and among long-term survivors, particularly for the less prevalent cancer types and younger people. Studies that focus on prevention are minimal and research covering low- and middle-income populations is limited.

Conclusion

Research is urgently needed into the possible impacts of long-term and late effects of cancer treatment on mental health and how these may be prevented, as increasing numbers of people live with and beyond cancer.

Full article at BMC Cancer

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [ID1485]

NICE |  October 2019 | Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [ID1485]

NICE has announced it has approved the medication for ovarian cancer- rucaparib-  can now be offered to women with relapsed ovarian, fallopian tube or peritoneal cancer, that has responded to platinum-based chemotherapy. Taken as a tablet, twice daily, it slows the progression of cancer by preventing cancer cells repairing so slowing down the tumour’s growth.

Around 1,350 people in England could benefit from this new treatment which will be available immediately through the CDF.

This approval is a change from the committee’s initial decision, where uncertainties in the evidence, and the price of rucaparib, meant it could not be recommended for routine use on the NHS.

Clinical trial evidence shows that rucaparib prevents cancer progression for twice as long as the placebo treatment (median of 10.8 months in the rucaparib group compared with 5.4 months in the placebo group). However, it is not known how this will translate into overall extended life expectancy due to incomplete trial data.

The drug company has since proposed an alternative price for rucaparib. If this revised commercial arrangement is supported with long-term overall survival data, rucaparib has the potential to be a cost-effective use of NHS resources. The committee therefore decided to include rucaparib in the CDF to allow this long-term data to be collected (Source: NICE).

The guidance is expected to be published on 13 November 2019.

Read the press release here

NICE Another treatment option for ovarian cancer approved for the Cancer Drugs Fund

In the news:

OnMedica Watchdog approves ovarian cancer treatment